05-18-04

Docket No: AM100013 C1

Patent

## THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re of Application of:

C. SATISHCHANDRAN and C. PACHUK

Application No.:

10/773,735

Group Art No.:

1632

Filed:

February 6, 2004 Examiner:

To Be Assigned

For:

METHOD AND COMPOSITIONS FOR INHIBITING THE FUNCTION

OF POLYNUCLEOTIDE SEQUENCES

Confirmation No.:

8739

Customer Number:

25291

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

1. Preliminary Statements

In accordance with 37 CFR 1.97 and 1.98, Applicants submit herewith patents, publications, or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR 1.56. This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) the information is material to the examination of this application; (iii) additional information material to the examination of this application does not exist; (iv) the information, protocols, results and the like reported by third parties are accurate or enabling; or (v) the information constitutes prior art to the subject invention.

## **CERTIFICATE OF MAILING 37 CFR §1.10**

I hereby certify that this paper and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date written below in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number ER672186164US addressed to the Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

5/17/04

Date

Docket No: AM100013 C1 Patent

2.	Identification of Time of Filing This Information Disclosure Statement								
		Inform	nation Disclosure Statement is filed within three months of the fili	na date of the anni	lication				
	a. b.	$\boxtimes$	is filed before the mailing date of a f			ts			
	C.	Ħ	is filed before the mailing date of a f						
	<u> </u>	<u> </u>	request for continued examination u						
	d.		is filed after the period specified in 2 mailing date of a final action under 3 a certification under 37 CFR 1.97(e)	(a), 2(b) or 2(c) ab 37 CFR 1.311. Thi	ove, but b s stateme	nt includes			
	e.		is filed after the mailing date of a fine before payment of the issue fee. The under 37 CFR 1.97(e), and (ii) the fe	al action or Notice is statement include	of Allowar des (i) a ce	nce but ertification			
3.			fication under 37 CFR 1.97(e) and 1. undersigned attorney certifies	704(d)					
	a.		that each item of information contain Statement was first cited in any com in a counterpart foreign application of filing of the statement, or	munication from a	foreign pa	atent office			
	b.		that no item of information contained Statement was cited in a communic counterpart foreign application or, to the certification after making reason individual designated in 37 CFR 1.5 the filing of the statement.	ation from a foreigi the knowledge of able inquiry, was k	n patent of the perso known to a	ffice in a n signing ny			
	C.		certifies that each item of information Disclosure Statement was cited in a application patent office in a counterreceived by any individual designate (30) days prior to the filing of the statement.	communication from part foreign appliced in 37 CFR 1.56(	om a foreigation and	gn was not			
		Newly Cited Information A legible copy of the patents, publications or other information cited on the attached form PTO 1449 is enclosed, except that no copy of a pending U.S. application is enclosed, and if this patent application was filed or entered the national stage after June 30, 2003, no copy of a U.S. patent or U.S. patent application publication is enclosed.							
		No conformate to the under	iously Cited Information opy of the patents, publications or oth PTO-1449 is enclosed because it ha e Office in a prior application which is er 35 USC 120.	s been previously relied upon for an	cited by or earlier fili	r submitted ng date			
		HUOL	application is Application Number	, filed on	of	for			

Docket No: AM100013 C1
Patent

a. b.	- Single						
Form	í PTO	O-1449 is enclosed in duplicate.					
	Fees	es Fee for filing under 37 CFR 1.97(c	c) or (d)	Fee: \$180.00	)		
Char	ge De	f Payment of Fees: eposit Account No. 01-1425 in the a te of this statement is enclosed.	mount of \$0	.00			
Instructions as to Overpayment/Underpayment: Credit any overpayment and charge any underpayment to Deposit Account No. 01-1425.							
		$\overline{\wedge}$		el la	terat		

J.Darrell Fontenot Attorney for Applicants Reg. No. 46,705

Wyeth Patent Law Department Five Giralda Farms Madison, NJ 07940 Tel. No. (845) 602-3144

## Complete if Known information 10/773,735 **Application Number** Filing Date February 6, 2004 INFORMATION DISCLOSURE STATEMENT BY APPLICANT First Named Inventor C. Satishchandran 1632 Group Art Unit as many sheets as necessary) **Examiner Name** To Be Assigned of Attorney Docket Number AM100013 C1

U.S. PATENT DOCUMENTS								
		U.S. Patent Doc	ument	<del></del>	B. t. (B. bli seller of	Pages, Columns, Lines,		
Examiner Initials*	Cite No.	Number (If known)	Kind Code (If Клоwn)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear		
	1.							

	FOREIGN PATENT DOCUMENTS										
Examiner	Cite No.	Foreign Patent Document			Name of Patentee or	Date of Publication of	Pages, Columns, Lines, Where Relevant				
Initials*		Office	Number	Kind Code (If Known)	Applicant of Cited document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T			
	2.	EP	0983,370	B1	Syngenta Limited	09-17-2003					

		OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
	3.		

Examiner Signature	Date Conside	ered
Cignatare	Obliside	700